Welcome to our dedicated page for Landos Biopharma news (Ticker: LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Landos Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Landos Biopharma's position in the market.
Landos Biopharma (NASDAQ: LABP) has announced significant progress in its autoimmune pipeline, showcasing robust preclinical data for its drug candidates. The company expects to submit an IND for omilancor, a topical psoriasis treatment, in 2H 2021, and for PX-69, an oral rheumatoid arthritis treatment, in 1H 2022. Preclinical studies indicate omilancor effectively reduces inflammation, while PX-69 shows promise in preserving joint structure and reducing disease severity. Both candidates will be presented at the AAI Annual Meeting from May 10-15, 2021.
Landos Biopharma (NASDAQ: LABP) appointed Tiago Girão as a Board member and Chair of the Audit Committee, bringing over 20 years of finance and operations experience in the life sciences sector. His previous roles include CFO at Cytori Therapeutics, where he raised over $120 million, and CFO at ProteoVant Therapeutics. CEO Josep Bassaganya-Riera highlighted Girão's expertise in strategic planning and capital raising, crucial for advancing Landos’ clinical development. The company focuses on developing oral therapeutics targeting autoimmune diseases, including ulcerative colitis and Crohn's disease.
Landos Biopharma (NASDAQ: LABP) announced the FDA clearance of its IND application for omilancor (BT-11), targeting Eosinophilic Esophagitis (EoE), an orphan disease with no current FDA-approved treatments. The company plans to initiate a Phase 1b study to evaluate the drug's safety and pharmacokinetics in 36 patients. Omilancor also has indications for ulcerative colitis and Crohn’s disease, aiming to address significant treatment gaps in autoimmune diseases. The clinical trial is expected to begin in the first half of 2022.
Landos Biopharma (NASDAQ: LABP) announced positive results from the Phase 1 study of NX-13, its first-in-class oral therapeutic for inflammatory bowel disease. The trial met all primary and secondary endpoints, demonstrating good tolerability with no serious adverse events reported. NX-13 targets the NLRX1 pathway and aims to provide a new treatment approach for ulcerative colitis. Following this success, the company plans to initiate a Phase 1b trial later this year and file additional Investigational New Drug applications. NX-13 shows promise in addressing autoimmune diseases effectively.
Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company, announced that Dr. Josep Bassaganya-Riera will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 12:00 PM EST. A live webcast will be available on the company's website, with an archived version to follow.
Landos focuses on oral therapeutics for autoimmune diseases, with lead asset BT-11 targeting ulcerative colitis and Crohn’s disease.
Landos Biopharma announced the pricing of its initial public offering (IPO) of 6,250,000 shares at $16.00 each, aiming for total gross proceeds of $100 million. The shares will trade on the Nasdaq under the symbol LABP starting February 4, 2021, with the offering set to close on February 8, 2021. A 30-day option for underwriters to purchase an additional 937,500 shares at the offering price is included. J.P. Morgan, Jefferies, and SVB Leerink are managing the offering.
Landos Biopharma has announced positive results from a Phase 2 trial of BT-11, an oral treatment for ulcerative colitis, demonstrating clinical remission rates up to 11.5% at week 12. The trial involved 198 patients and showed normalization of fecal calprotectin levels in over 40% of treated patients. BT-11 was well tolerated with a similar adverse event profile to placebo. Following this success, Landos plans to initiate a Phase 3 trial in ulcerative colitis and a Phase 2 trial in Crohn’s disease in 2021, aiming to further validate the LANCL2 pathway's therapeutic potential.